A Systems Medicine approach to multimorbidity. Towards personalised care for patients with Chronic Obstructive Pulmonary Disease

[eng] BACKGROUND: Multimorbidity (i.e. the presence of more than one chronic disease in the same patient) and comorbidity (i.e. the presence of more than one chronic disease in the presence of an index disease) are main sources of dysfunction in chronic patients and avoidable costs in conventional health systems worldwide. By affecting a majority of elderly population worldwide, multimorbidity prompts the need for revisiting the single disease approach followed by contemporary clinical practice and elaborate strategies that target shared mechanisms of associated diseases with the potential of preventing, decelerating or even halting multimorbid disease progression. However, our current understanding on disease interactions is rather limited, and although many disorders have been associated based on their shared molecular traits and their observed co-occurrence in different populations, no comprehensive approach has been outlined to translate this knowledge into clinical practice. The advent of novel measurement technologies (e.g. omics) and recent initiatives on digital health (e.g. registries, electronic health records) are facilitating access to an enormous amount of patient-related information from whole populations to molecular levels. State-of-the art computational models and machine learning tools demonstrate high potential for health prediction and together with systems biology are shaping the practicalities of systems medicine. Given the extremely long and expensive bench to clinics cycles of the biomedical sector, systems medicine promises a fast track approach where scientific evidence support clinical care, while simultaneously collected insights from daily clinical practice promote new scientific discoveries and optimize healthcare. The PhD thesis aims to explore multimorbidity from a systems medicine perspective on the concrete and practical use case of chronic obstructive pulmonary disease (COPD). COPD constitutes an ideal use case due to several factors, including: i) its high impact on healthcare and its ever-increasing burden; ii) its heterogeneous disease manifestations, and progress, often involving extra-pulmonary effects, including highly prevalent comorbidities (e.g. type 2 diabetes mellitus, cardiovascular disorders, anxiety-depression and lung cancer); and, iii) its well described systemic effects that are suggested associations with comorbidities in terms of underlying mechanisms. HYPOTHESIS: The central hypothesis of the PhD thesis builds on the emerging biological evidence that clustering of comorbid conditions, a phenomenon seen in complex chronic patients, could be due to shared abnormalities in relevant biological pathways (i.e. bioenergetics, inflammation and tissue remodelling). It is assumed that a systems understanding of the patient conditions may help to uncover the molecular mechanisms and lead to the design of preventive and targeted therapeutic strategies aiming at modulating patient prognosis. The PhD thesis focuses on non-pulmonary phenomena of COPD; that is, systemic effects and comorbidities, often observed in patients with COPD as a paradigm of complex chronic disease. OBJECTIVES: The general objective of the PhD thesis is threefold: i) to investigate molecular disturbances at body systems level that may lead to a better understanding of characteristic systemic effects and comorbidities of patients with COPD; ii) to analyse population level patterns of COPD comorbidities and investigate their role in the health risk of patients with COPD; and, iii) to explore technological strategies and tools that facilitate the transfer of the collected knowledge on comorbidity into clinical practice. MAIN FINDINGS: Firstly, the PhD thesis introduced a novel knowledge management tool for targeted molecular analysis of underlying disease mechanisms of skeletal muscle dysfunction in patients with COPD. Second, a network analysis approach was outlined to further study this systemic effect, as well as the causes of abnormal adaptation of COPD muscle to exercise training. Furthermore, this work together with three other studies also aimed to reveal the general underlying causes of comorbidity clustering in COPD, using different modelling approaches. Overarching outcome of these studies indicates abnormalities in the complex co-regulation of core biological pathways (i.e. bioenergetics, inflammation, oxidative stress and tissue remodelling) both on muscle and body systems level (blood, lung), which paves the way for the development of novel pharmacological and non-pharmacological preventive interventions on non- pulmonary phenomena in patients with COPD. Furthermore, results indicated strong relation of muscle related dysregulations to aerobic capacity, in opposed to pulmonary severity of COPD. These findings have far reaching potential in COPD care, starting from defining the need for better characterization of exercise performance in the clinic practice and the promotion of physical activity from early stages of the disease. This PhD thesis also generated outcomes with respect to the risk of multimorbidity in patients with COPD using a population health approach. The thesis validated that patients with COPD are in increased risk to co-occur with other diseases compared to non-COPD patients, regardless of the population and healthcare system specificities of different regions (i.e. Catalonia, US). These findings indicated the potential role of multimorbidity as a risk factor for COPD, that was evaluated in the PhD thesis by constructing health risk assessment models to predict unexpected medical events in patients with COPD. The promising performance of the models and the prominent role of multimorbidity in these models presented a powerful argument for its role in clinical staging of the disease and their potential in clinical decision support. CONCLUSIONS: The PhD thesis achieved main points of the general objectives, namely: i) to perform a systems analysis of patients with COPD by investigating molecular disturbances at body systems level leading to a better understanding of characteristic systemic effects and comorbidities of patient with COPD; ii) to analyse population level patterns of COPD comorbidities and investigate their role in the health risk of patients with COPD; and iii) to explore technological strategies and tools that facilitate the transfer of the collected knowledge on comorbidity into clinical practice. Accordingly, the following conclusions arise: 1. Non-pulmonary manifestations in patients with Chronic Obstructive Pulmonary Disease (COPD) have a major negative impact on: highly relevant clinical events, use of healthcare resources and prognosis. Accordingly, the following indications were made: a. Actionable insights on non-pulmonary phenomena should be included in the clinical staging of these patients in an operational manner. b. Management of patients with COPD should be revisited to incorporate an integrative approach to non-pulmonary phenomena. c. Innovative cost-effective interventions, and pharmacological and non- pharmacological treatments targeting prevention of non-pulmonary manifestations in patients with COPD should be developed, and properly assessed. 2. Abnormal co-regulation of core biological pathways (i.e. bioenergetics, inflammation, tissue remodelling and oxidative stress), both in skeletal muscle and at body systems level, are common characteristics of patients with COPD, which potentially play a major role in comorbidity clustering. 3. Consistent relationships between cardiovascular health, skeletal muscle dysfunction and clinical outcomes in patients with COPD was identified, which makes it a priority to characterize patient exercise performance and physical activity in the clinic, and to adopt early cardiopulmonary rehabilitation strategies to modulate prognosis and prevent comorbidity clustering in these patients. 4. Multimorbidity is a strong predictor of unplanned medical events in patients with COPD and shows high potential to be used for personalized health risk prediction and service workflow selection. 5. Personalized health risk prediction was identified as a high potential tool for the integration and transfer of scientific evidence on multimorbidity to daily clinical practice. Limiting factors of its present applicability were explored and implementation strategies based on cloud computing solutions were proposed.[cat] INTRODUCCIÓ: Tant la multimorbiditat (la presència de més d'una malaltia crònica en el mateix pacient), com la comorbiditat (la presència de més d'una malaltia crònica quan hi ha una malaltia de referència) són una font important de disfuncions en l’atenció sanitària dels pacients crònics i generen importants despeses evitables en sistemes de salut arreu del món. La multimorbiditat/comorbiditat afecta la majoria de població de més de 65 anys. El seu gran impacte sanitari i social fa necessària la revisió d’aspectes essencials de la pràctica mèdica convencional, molt enfocada al tractament de cada malaltia de forma aïllada. En aquest sentit, cal elaborar estratègies que considerin els mecanismes biològics comuns entre patologies, per tal de prevenir, retardar o fins i tot aturar la progressió del fenomen. Malauradament, el poc coneixement dels mecanismes biològics que modulen les interaccions entre malalties és un factor limitant important. Hi ha estudis sobre els mecanismes moleculars comuns entre malalties i s’han realitzat anàlisis poblacionals de la multimorbiditat, però no existeix encara una aproximació holística per tal de traduir aquest coneixement a la pràctica clínica. L’aparició de noves tecnologies òmiques, així com iniciatives recents en l’àmbit de la salut digital, han facilitat l'accés a una quantitat enorme d'informació dels pacients, tant a nivell poblacional com a nivell molecular. A més, les eines computacionals i d'aprenentatge automàtic existents estan demostrant un gran potencial predictiu que, conjuntament amb les metodologies de la biologia de sistemes, estan conformant els aspectes pràctics del desplegament de la medicina de sistemes. De forma progressiva, aquesta última esdevé una via efectiva per accelerar el rol de l’evidència científica com a suport a la atenció clínica. De forma recíproca, la digitalització sistemàtica de la pràctica clínica diària, permet la generació de noves descobertes científiques i la optimització de l’assistència sanitària. Aquesta tesis doctoral pretén explorar la multimorbiditat des d’una perspectiva de medicina de sistemes, considerant com a cas d'ús concret i pràctic la malaltia pulmonar obstructiva crònica (MPOC). La MPOC constitueix un cas d'ús ideal a causa de diversos factors: i) el seu alt impacte a nivell sanitari; ii) la heterogeneïtat en quant a manifestacions i progrés, sovint amb efectes extra-pulmonars, incloent de forma freqüent comorbiditats com la diabetis mellitus tipus 2, trastorns cardiovasculars, l'ansietat-depressió i el càncer de pulmó; i, iii) els efectes sistèmics de la malaltia pulmonar, que podrien presentar mecanismes biològics comuns a algunes comorbiditats. HIPÒTESIS: La hipòtesi central d’aquesta tesis doctoral considera que la multimorbiditat podria explicar-se per alteracions en les xarxes de regulació de mecanismes biològics rellevants com la bioenergètica, inflamació i remodelació de teixits. En aquest sentit, l’anàlisi holística del problema podria millorar la comprensió dels mecanismes moleculars que modulen les associacions entre malalties i, per tant, facilitar el disseny d'estratègies terapèutiques preventives i dirigides a modular el pronòstic dels pacients. Aquesta tesis doctoral estudia els fenòmens extra-pulmonars de la MPOC; és a dir, efectes sistèmics (disfunció del múscul esquelètic) i comorbiditats, com a paradigma de malalties cròniques complexes. OBJECTIUS: L'objectiu general d’aquesta tesis doctoral és triple: i) l’anàlisi holístic de pacients amb MPOC amb focus en la disfunció muscular i les comorbiditats; ii) avaluar el paper de les comorbiditats en el risc de salut dels pacients amb MPOC, tant a nivell poblacional com individual; i, iii) explorar estratègies tecnològiques i eines de salut digital que facilitin la transferència de coneixement a la pràctica clínica diària. RESULTATS: El primer manuscrit de la tesi descriu una nova eina de gestió del coneixement per l’anàlisi molecular dels mecanismes de disfunció del múscul esquelètic en pacients amb MPOC. També dins el primer objectiu de la tesi, s’efectua un anàlisi de xarxes orientat a la identificació de mòduls biològics explicatius de la disfunció muscular i de l’adaptació anòmala d’aquests malalts a l’entrenament físic, tal com es descriu en el segon manuscrit. Els tres articles següents exploren, des de diferents perspectives, l’impacte i mecanismes de les comorbiditats en els pacients amb MPOC. Els principals resultats d'aquests estudis indiquen una complexa i anormal regulació de vies biològiques principals, com es el cas de la bioenergètica, inflamació, estrès oxidatiu i remodelació de teixits, tant a nivell del múscul com a nivell sistèmic (sang, pulmó). Aquests resultats obren noves vies per a intervencions preventives, tant farmacològiques com no farmacològiques, sobre els fenòmens no pulmonars que presenten els pacients amb MPOC. Els resultats indiquen una associació de les alteracions musculars amb la capacitat aeròbica, i no pas amb la gravetat de la malaltia pulmonar. Aquestes troballes tenen un gran potencial en la millora de la gestió dels pacients amb MPOC, començant per la necessitat d’una millor caracterització de la capacitat aeròbica en la pràctica clínica i la promoció d'activitat física des de les primeres etapes de la malaltia. La tesi també ha generat resultats d’interès en relació amb el risc de multimorbiditat en pacients amb MPOC, mitjançant un enfocament de salut poblacional. Els resultats evidencien que els pacients amb MPOC presenten un risc mes elevat de comorbiditat que els pacients sense MPOC, independentment de les especificitats de la població i del sistema sanitari de les àrees analitzades (Catalunya, EUA). La tesi també demostra el paper de la multimorbiditat com a factor modulador del risc clínic dels pacients amb MPOC. Aquests resultats indiquen l’interès de l’ús de la multimobiditat en l’estadiatge dels pacients amb MPOC i en l’elaboració d’eines de suport al procés de decisió clínica. CONCLUSIONS: Aquesta tesi doctoral ha assolit els objectius generals plantejats i proposa les següents conclusions: 1. Les manifestacions no pulmonars en els pacients amb malaltia pulmonar obstructiva crònica (MPOC) tenen un impacte negatiu respecte a esdeveniments de gran rellevància clínica, ús de recursos sanitaris i pronòstic. En conseqüència, es fan les següents recomanacions: a. Els fenòmens no pulmonars de la MPOC s’haurien d’incloure de manera operativa en l’estadiatge d'aquests pacients. b. S’hauria de redefinir la gestió clínica dels pacients amb MPOC tot incorporant un enfocament holístic dels fenòmens no pulmonars. c. S’haurien de desenvolupar i avaluar correctament noves intervencions, farmacològiques i no farmacològiques, per a la prevenció de les manifestacions no pulmonars en pacients amb MPOC. 2. Les alteracions de la regulació de vies biològiques rellevants com la bioenergètica, inflamació, estrès oxidatiu i la remodelació de teixits a nivell del múscul esquelètic, i també a nivell sistèmic, s’observa en els pacients amb MPOC i pot tenir un paper important en les co-morbiditats. 3. Les relacions entre alteracions cardiovasculars, disfunció del múscul esquelètic i altres aspectes clínics dels pacients amb MPOC, indiquen la necessitat de caracteritzar la capacitat aeròbica i els nivells d'activitat física en la pràctica clínica, així com la implementació d’estratègies de rehabilitació cardiopulmonar en les primeres etapes de la malaltia, per tal de modular la prognosis dels malalts i prevenir l’aparició de comorbiditats. 4. La multimorbiditat és un bon predictor d’esdeveniments clínics rellevants en pacients amb MPOC i mostra un gran potencial per a personalitzar l’estimació de risc i la selecció de serveis. 5. La predicció de risc de forma personalitzada s’ha identificat com una eina amb molt potencial per a la gestió de la multimorbiditat en la pràctica clínica diària. S’han explorat els factors limitants de la seva aplicabilitat i s’han proposat estratègies d'implementació d’eines predictives adients, basades en solucions de computació en el núvol.[spa] INTRODUCCIÓN: Tanto la multimorbilidad (la presencia de más de una enfermedad crónica en un mismo paciente) como la comorbilidad (la presencia de más de una enfermedad crónica en presencia de una enfermedad de referencia) son una fuente importante de disfunciones en la atención sanitaria de los pacientes crónicos y generan importantes costes evitables en los sistemas de salud de todo el mundo. La multimorbilidad/comorbilidad afecta a la mayoría de la población de más de 65 años. Debido a su gran impacto sanitario y social, resulta necesaria la revisión de aspectos esenciales de la práctica médica convencional, muy enfocada en el tratamiento de cada enfermedad de forma aislada. En este sentido, es necesario elaborar estrategias que consideren mecanismos biológicos comunes entre patologías, con el fin de prevenir, retrasar o incluso detener la progresión del fenómeno. Desgraciadamente, el escaso conocimiento de los mecanismos biológicos que modulan las interacciones entre enfermedades es un factor limitante importante. Existen estudios sobre los mecanismos moleculares comunes entre enfermedades y se han realizados análisis poblaciones de la multimorbilidad, pero no existe aún una aproximación holística que permita traducir este conocimiento a la práctica clínica. La aparición de nuevas tecnologías ómicas, así como recientes iniciativas en el ámbito de la salud digital, han facilitado el acceso a una cantidad enorme de información sobre los pacientes, tanto a nivel poblacional como a nivel molecular. Además, las herramientas computacionales y de aprendizaje automático existentes demuestran un gran potencial predictivo que, conjuntamente con las metodologías de biología de sistemas, están conformando los aspectos prácticos de la medicina de sistemas. De manera progresiva esta última se está convirtiendo en una vía efectiva para acelerar el papel de la evidencia científica como soporte a la atención clínica. De forma recíproca, la digitalización sistemática de la práctica clínica diaria permite la generación de nuevos descubrimientos científicos y la optimización de la asistencia sanitaria. Esta tesis doctoral pretende explorar la multimorbilidad desde una perspectiva de medicina de sistemas, considerando como caso de uso concreto y práctico la enfermedad pulmonar obstructiva crónica (EPOC). La EPOC constituye un caso de uso ideal debido a diversos factores: i) su alto impacto a nivel sanitario; ii) la heterogeneidad en cuanto a manifestaciones y progreso, a menudo con efectos extra pulmonares, incluyendo de forma frecuente comorbilidades como la diabetes mellitus tipo 2, trastornos cardiovasculares, la ansiedad-depresión y el cáncer de pulmón; y, iii) los efectos sistémicos de la enfermedad pulmonar, que podrían presentar mecanismos biológicos comunes a algunas comorbilidades. HIPÓTESIS: La hipótesis central de esta tesis doctoral considera que la multimorbilidad podría explicarse por alteraciones en las redes de regulación de mecanismos biológicos relevantes como la bioenergética, inflamación y remodelación de tejidos. En este sentido, el análisis holístico del problema podría mejorar la comprensión de los mecanismos moleculares que modulan las asociaciones entre enfermedades y, por tanto, facilitar el diseño de estrategias terapéuticas preventivas y dirigidas a modular el pronóstico de los pacientes. Esta tesis doctoral estudia los fenómenos extra pulmonares de la EPOC; es decir, efectos sistémicos (disfunción del músculo esquelético) y comorbilidades, como paradigma de enfermedades crónicas complejas. OBJETIVOS: El objetivo general de esta tesis doctoral es triple: i) el análisis holístico de pacientes con EPOC focalizando en la disfunción muscular y la comorbilidades; ii) evaluar el papel de las comorbilidades en el riesgo de salud de los pacientes con EPOC, tanto a nivel poblacional como individual; y, iii) explorar estrategias tecnológicas y herramientas de salud digital que faciliten la transferencia de conocimiento a la práctica clínica diaria. RESULTADOS: El primer manuscrito de la tesis describe una nueva herramienta de gestión del conocimiento para el análisis molecular de los mecanismos de disfunción del músculo esquelético en pacientes con EPOC. Incluido en el primer objetivo de la tesis, se efectúa un análisis de redes orientado a la identificación de módulos biológicos que explican la disfunción muscular y la adaptación anómala de estos pacientes al entrenamiento físico, tal y cómo se describe en el segundo manuscrito. Los tres artículos siguientes exploran, desde perspectivas diferentes, el impacto y mecanismos de las comorbilidades en los pacientes con EPOC. Los principales resultados de estos estudios indican una compleja y anormal regulación de vías biológicas principales, como es el caso de la bioenergética, inflamación, estrés oxidativo y remodelación de tejidos, tanto a nivel del músculo como a nivel sistémico (sangre, pulmón). Estos resultados abren nuevas vías para intervenciones preventivas, tanto farmacológicas como no farmacológicas, sobre los fenómenos no pulmonares que presentan los pacientes con E

Neuro-WiFi: A Novel Neuronal Connection Underlies the Potential Interventional Target

Neuro-WiFi, as a non-physical connection-related neural network that efficiently links various regions of the brain, facilitates swift transfer of information and fostering communication among neurons. It is a significant advancement in neuroscience, providing valuable understanding of the intricate connections between neurons and opening up possibilities for precise interventions. This unique neural connection entails the transfer of information between remote parts of the brain via a network resembling WiFi signal. Neuro-WiFi has the potential to greatly enhance our understanding of how information is processed and sent in the brain by facilitating fast and accurate communication over long distances. Envision the ability to modify the neuro-WiFi network to enhance cognitive performance or restore impaired neural circuits. Furthermore, this neuronal connection could have substantial ramifications for the development of therapeutic approaches to address neurological conditions like Alzheimer’s disease or epilepsy. Despite the remaining knowledge gaps around this remarkable phenomenon, through additional investigations, we believe that the mysteries of neuro-WiFi would be extensively uncovered and precise therapies that could profoundly transform our comprehension of brain function and enhance patient outcomes would be provided in the future. &nbsp

Pursuit of precision medicine: Systems biology approaches in Alzheimer\u27s disease mouse models.

Alzheimer\u27s disease (AD) is a complex disease that is mediated by numerous factors and manifests in various forms. A systems biology approach to studying AD involves analyses of various body systems, biological scales, environmental elements, and clinical outcomes to understand the genotype to phenotype relationship that potentially drives AD development. Currently, there are many research investigations probing how modifiable and nonmodifiable factors impact AD symptom presentation. This review specifically focuses on how imaging modalities can be integrated into systems biology approaches using model mouse populations to link brain level functional and structural changes to disease onset and progression. Combining imaging and omics data promotes the classification of AD into subtypes and paves the way for precision medicine solutions to prevent and treat AD

Artificial intelligence for dementia drug discovery and trials optimization

Drug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress. Opportunities arise at multiple stages in the therapy pipeline and the growing availability of large medical data sets opens possibilities for big data analyses to answer key questions in clinical and therapeutic challenges. However, before this goal is reached, several challenges need to be overcome and only a multi-disciplinary approach can promote data-driven decision-making to its full potential. Herein we review the current state of machine learning applications to clinical trial design and drug discovery, while presenting opportunities and recommendations that can break down the barriers to implementation

Artificial intelligence for dementia drug discovery and trials optimization

Drug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress. Opportunities arise at multiple stages in the therapy pipeline and the growing availability of large medical data sets opens possibilities for big data analyses to answer key questions in clinical and therapeutic challenges. However, before this goal is reached, several challenges need to be overcome and only a multi‐disciplinary approach can promote data‐driven decision‐making to its full potential. Herein we review the current state of machine learning applications to clinical trial design and drug discovery, while presenting opportunities and recommendations that can break down the barriers to implementation

Artificial intelligence for dementia drug discovery and trials optimization

Drug discovery and clinical trial design for dementia have historically been challenging. In part these challenges have arisen from patient heterogeneity, length of disease course, and the tractability of a target for the brain. Applying big data analytics and machine learning tools for drug discovery and utilizing them to inform successful clinical trial design has the potential to accelerate progress. Opportunities arise at multiple stages in the therapy pipeline and the growing availability of large medical data sets opens possibilities for big data analyses to answer key questions in clinical and therapeutic challenges. However, before this goal is reached, several challenges need to be overcome and only a multi-disciplinary approach can promote data-driven decision-making to its full potential. Herein we review the current state of machine learning applications to clinical trial design and drug discovery, while presenting opportunities and recommendations that can break down the barriers to implementation

Computational and chemical approaches to drug repurposing

Drug repurposing, which entails discovering novel therapeutic applications for already existing drugs, provides numerous benefits compared to conventional drug discovery methods. This strategy can be pursued through two primary approaches: computational and chemical. Computational methods involve the utilization of data mining and bioinformatics techniques to identify potential drug candidates, while chemical approaches involve experimental screens oriented to finding new potential treatments based on existing drugs. Both computational and chemical methods have proven successful in uncovering novel therapeutic uses for established drugs. During my PhD, I participated in several experimental drug repurposing screens based on high-throughput phenotypic approaches. Finally, attracted by the potential of computational drug repurposing pipelines, I decided to contribute and generate a web platform focused on the use of transcriptional signatures to identify potential new treatments for human disease. A summary of these studies follows: In Study I, we utilized the tetracycline repressor (tetR)-regulated mechanism to create a human osteosarcoma cell line (U2OS) with the ability to express TAR DNA-binding protein 43 (TDP-43) upon induction. TDP-43 is a protein known for its association with several neurodegenerative diseases. We implemented a chemical screening with this system as part of our efforts to repurpose approved drugs. While the screening was unsuccessful to identify modulators of TDP-43 toxicity, it revealed compounds capable of inhibiting the doxycyclinedependent TDP-43 expression. Furthermore, a complementary CRISPR/Cas9 screening using the same cell system identified additional regulators of doxycycline-dependent TDP43 expression. This investigation identifies new chemical and genetic modulators of the tetR system and highlights potential limitations of using this system for chemical or genetic screenings in mammalian cells. In Study II, our objective was to reposition compounds that could potentially reduce the toxic effects of a fragment of the Huntingtin (HTT) protein containing a 94 amino acid long glutamine stretch (Htt-Q94), a feature of Huntington's disease (HD). To achieve this, we carried out a high-throughput chemical screening using a varied collection of 1,214 drugs, largely sourced from a drug repurposing library. Through our screening process, we singled out clofazimine, an FDA-approved anti-leprosy drug, as a potential therapeutic candidate. Its effectiveness was validated across several in vitro models as well as a zebrafish model of polyglutamine (polyQ) toxicity. Employing a combination of computational analysis of transcriptional signatures, molecular modeling, and biochemical assays, we deduced that clofazimine is an agonist for the peroxisome proliferator-activated receptor gamma (PPARγ), a receptor previously suggested to be a viable therapeutic target for HD due to its role in promoting mitochondrial biogenesis. Notably, clofazimine was successful in alleviating the mitochondrial dysfunction triggered by the expression of Htt-Q94. These findings lend substantial support to the potential of clofazimine as a viable candidate for drug repurposing in the treatment of polyQ diseases. In Study III, we explored the molecular mechanism of a previously identified repurposing example, the use of diethyldithiocarbamate-copper complex (CuET), a disulfiram metabolite, for cancer treatment. We found CuET effectively inhibits cancer cell growth by targeting the NPL4 adapter of the p97VCP segregase, leading to translational arrest and stress in tumor cells. CuET also activates ribosomal biogenesis and autophagy in cancer cells, and its cytotoxicity can be enhanced by inhibiting these pathways. Thus, CuET shows promise as a cancer treatment, especially in combination therapies. In Study IV, we capitalized on the Molecular Signatures Database (MSigDB), one of the largest signature repositories, and drug transcriptomic profiles from the Connectivity Map (CMap) to construct a comprehensive and interactive drug-repurposing database called the Drug Repurposing Encyclopedia (DRE). Housing over 39.7 million pre-computed drugsignature associations across 20 species, the DRE allows users to conduct real-time drugrepurposing analysis. This can involve comparing user-supplied gene signatures with existing ones in the DRE, carrying out drug-gene set enrichment analyses (drug-GSEA) using submitted drug transcriptomic profiles, or conducting similarity analyses across all database signatures using user-provided gene sets. Overall, the DRE is an exhaustive database aimed at promoting drug repurposing based on transcriptional signatures, offering deep-dive comparisons across molecular signatures and species. Drug repurposing presents a valuable strategy for discovering fresh therapeutic applications for existing drugs, offering numerous benefits compared to conventional drug discovery methods. The studies conducted in this thesis underscore the potential of drug repurposing and highlight the complementary roles of computational and chemical approaches. These studies enhance our understanding of the mechanistic properties of repurposed drugs, such as clofazimine and disulfiram, and reveal novel mechanisms for targeting specific disease pathways. Additionally, the development of the DRE platform provides a comprehensive tool to support researchers in conducting drug-repositioning analyses, further facilitating the advancement of drug repurposing studies

White Paper 4: Challenges In Biomedicine & Health

Publicado en Madrid, 231 p. ; 17 cm.A lesson that we have learned from the pandemia caused by coronavirus is that solutions in health require coordinated actions. Beside this and other emerging and re-emerging infectious diseases, millions of Europeans are suffering a plethora of disorders that are currently acquiring epidemic dimensions, including cancer, rare diseases, pain and food allergies, among others. New tools for prevention, diagnosis and treatment need to be urgently designed and implemented using new holistic and multidisciplinary approaches at three different levels (basic research, translational/clinical and public/social levels) and involving researchers, clinicians, industry and all stakeholders in the health system. The CSIC is excellently positioned to lead and coordinate these challenges in Biomedicine and Health.Peer reviewe

Pathway curator: an online webserver extracting genes and interactions from figures

In the biomedical literature, gene pathways are frequently included. Many high-quality gene pathways are illustrated in the form of visuals and text, making them valuable study tools for biological processes and precision medicine. Pathway maps and literature texts provide researchers with access to a huge number of new biological treatments. For general usage, these pathway maps should be logically ordered, coordinated, and converted into a computer-readable format. Currently, keeping up with the rapid increase of the literature requires laborious extraction of information from a publication at a time. A gene pathway map recognition system is devised and implemented in this study. Based on the pathway map and relevant information supplied by users, the system extracts gene identity and gene interaction information, and the automated extraction from pathway maps is efficient. Furthermore, the tool offers users with a full view of a certain illness's pathway, which is useful for researchers and can speed up the research process in a variety of biomedical applications. This thesis first explains the project's goal and provides the background information. The project's design ideas are then presented, as well as an analysis of the system and introductions to related platforms. After that, the system's implementations are described one by one, together with the deployment and testing processes. Finally, potential improvements and future work are discussed.Includes bibliographical references

Artificial Intelligence in Oncology Drug Discovery and Development

There exists a profound conflict at the heart of oncology drug development. The efficiency of the drug development process is falling, leading to higher costs per approved drug, at the same time personalised medicine is limiting the target market of each new medicine. Even as the global economic burden of cancer increases, the current paradigm in drug development is unsustainable. In this book, we discuss the development of techniques in machine learning for improving the efficiency of oncology drug development and delivering cost-effective precision treatment. We consider how to structure data for drug repurposing and target identification, how to improve clinical trials and how patients may view artificial intelligence